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We read with interest editorial on the National Institute for Health and Care Excellence (NICE) 
menopause guideline,1 and their comments on the presentation of evidence underpinning the 
guideline’s recommendations.2 
We dispute their allegation that “methodological deficiencies undermine its conclusions.” The 
development of this guideline was based on a rigorous methodological approach involving a complex 
meta-analysis, known as a network meta-analysis. This method was used to assess the relative 
effectiveness of different treatments (pharmacological and non-pharmacological) to reduce the 
occurrence of vasomotor symptoms. This complex meta-analysis is methodologically superior to 
conventional meta-analyses because it allows the simultaneous comparison of different treatments to 
achieve an outcome for the population of interest (in this case, women in menopause). All the relevant 
peer reviewed publications looking at pharmacological (such as hormone replacement therapy; HRT) 
and non-pharmacological interventions (such as relaxation) that met the review protocol set by the 
guideline committee were considered for inclusion. However, some references mentioned in Hickey and 
Banks’s editorial did not meet these requirements, considered different outcomes (sleep, quality of life) 
that were not prioritised for review during guideline development, or were published too late for 
inclusion. The guideline committee also considered evidence in a conventional meta-analysis for other 
outcomes that commonly affect women in menopause—mood and depression (not clinical depression), 
sexual difficulties, and musculoskeletal symptoms—which are all domains of women’s quality of life. 
Although there were constraints of time and resources on the number of outcomes selected for review, 
the committee considered that the selected outcomes were adequate for their decision making. 
We strongly refute the authors’ argument that “the guideline lacks appropriate and complex 
quantitative summary estimates of the risks and benefits from taking menopausal hormone therapy.” 
The evidence was synthesised separately for the different long term outcomes (including risks) that may 
be associated with HRT (cardiovascular disease, stroke, breast cancer, osteoporosis, fractures) for two 
main reasons. Firstly, because the baseline estimation of risk is different across these disorders, and 
secondly to communicate clearly the independent risks that may be associated with HRT for women 
who might place different degrees of importance on these diseases. This evidence was presented 
separately for randomised controlled trials (RCTs) and observational studies owing to inherent 
methodological differences that affect the confidence of risk estimates, as indicated by the Cochrane 
handbook3 and GRADE methodology.4 The duration of HRT use was assessed separately during the 
guideline development, and disease risk associated with different durations of HRT use has been 
presented. The guideline committee recognised that the communication needs of women who were 
current or past users, or who had used HRT for different time intervals, might differ. We therefore 
decided that this would be the most appropriate method of presenting risks. In addition, the authors 
misread the presentation of evidence; the recommendations are based on the best available evidence 
(both RCT and observational data) and it is the RCT evidence that specifically includes women aged 50-
59 at the time of enrolment in the RCT. The data describing the papers included in the meta-analyses 
and the forest plots are described fully in appendices H-K 
(https://www.nice.org.uk/guidance/ng23/evidence/appendices-ik-559549264). The evidence 
statements synthesising the results are described in the full guideline 
(https://www.nice.org.uk/guidance/ng23/evidence/full-guideline-559549261 ). 
However, we agree with the authors that “the clinical challenge of HRT is balancing the benefits of 
symptomatic relief against the risks of disease” as the new NICE menopause guideline presents the risks 
and benefits for HRT and recommends adopting an individualised approach when discussing different 
treatment options with women. The aim of the NICE guidance is to inform healthcare professionals and 
their patients about the menopause and to improve and standardise care across the UK; we hope to 
achieve this in the future. 
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